Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?

Intensity-modulated radiation therapy (IMRT) has represented a technical milestone that has facilitated the clinical implementation. The purpose of this study was to evaluate the prognostic value of maximum primary tumor diameter (MPTD) in patients with nasopharyngeal carcinoma (NPC) treated using I...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2015-04, Vol.15 (1), p.305, Article 305
Main Authors: Chen, Yong, Hu, Xue-Feng, Wang, Yan, Chen, Hai-Yang, Yang, Lin, Liu, Li-Zhi, Cui, Chun-Yan, Liu, Dong-Sheng, Liang, Shao-Bo
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma
Care and treatment
Female
Follow-Up Studies
Health aspects
Humans
Male
Metastasis
Middle Aged
Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms - diagnosis
Nasopharyngeal Neoplasms - mortality
Nasopharyngeal Neoplasms - radiotherapy
Neoplasm Staging
Prognosis
Radiotherapy, Intensity-Modulated - methods
Retrospective Studies
Survival Rate - trends
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intensity-modulated radiation therapy (IMRT) has represented a technical milestone that has facilitated the clinical implementation. The purpose of this study was to evaluate the prognostic value of maximum primary tumor diameter (MPTD) in patients with nasopharyngeal carcinoma (NPC) treated using IMRT. Five-hundred and sixty-six patients with non-metastatic, histologically-confirmed NPC were retrospectively reviewed. MPTD was measured using magnetic resonance imaging (MRI). All patients were treated using IMRT; 87.5% (456/521) of patients with Stage T3-T4/N1-N3 disease also received cisplatin-based chemotherapy. Receiver operating characteristic (ROC) curves were used to identify the optimal MPTD cut-off point and examine the prognostic value of combining MPTD with the current T classification criteria. Median follow-up for all patients was 36 months (range, 1-52 months). The 3-year overall survival (OS), failure-free survival (FFS), distant metastasis-free survival (DMFS), and local relapse-free survival (LRFS) rates for patients with a MPTD ≤41 vs. >41 mm were 96.1% vs. 85.4%, 93.7% vs. 74.7%, 96.1% vs. 79.7%, and 98.1% vs. 92.9%, respectively (all P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-015-1288-8